Why the study?
Does spironolactone improve endothelial function, vascular ACE activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment?
Does spironolactone improve endothelial function, vascular ACE activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment?
Spironolactone improves vascular function and prognostic markers in patients with mild heart failure already on optimal medical therapy including beta-blockers.
No takes yet. Share an insight, caveat, or question.
Supports spironolactone addition in mild HF on optimal therapy; extends mineralocorticoid antagonism benefits to endothelial and prognostic markers.
J. Emyr Macdonald (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: